218 related articles for article (PubMed ID: 23877700)
1. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study.
Tsai MH; Chen CL; Chang HJ; Chuang TC; Chiu CH
J Glob Antimicrob Resist; 2024 Jun; 37():93-99. PubMed ID: 38552878
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
Corbett D; Wise A; Birchall S; Warn P; Baines SD; Crowther G; Freeman J; Chilton CH; Vernon J; Wilcox MH; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1751-6. PubMed ID: 25652750
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2012 Jun; 56(6):3448-52. PubMed ID: 22391542
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008].
Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.
Goldstein EJ; Citron DM; Tyrrell KL
Antimicrob Agents Chemother; 2014; 58(2):1187-91. PubMed ID: 24247123
[TBL] [Abstract][Full Text] [Related]
13. Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.
Wang FD; Liao CH; Lin YT; Sheng WH; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):2041-52. PubMed ID: 24930042
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
Finegold SM; Bolanos M; Sumannen PH; Molitoris DR
Antimicrob Agents Chemother; 2009 Sep; 53(9):3996-4001. PubMed ID: 19581457
[TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.
Dubreuil L; Houcke I; Mouton Y; Rossignol JF
Antimicrob Agents Chemother; 1996 Oct; 40(10):2266-70. PubMed ID: 8891127
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of bovine summer mastitis bacteria to antimicrobial agents.
Jousimies-Somer H; Pyörälä S; Kanervo A
Antimicrob Agents Chemother; 1996 Jan; 40(1):157-60. PubMed ID: 8787898
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
[TBL] [Abstract][Full Text] [Related]
20. In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.
Weiss W; Pulse M; Vickers R
Antimicrob Agents Chemother; 2014 Oct; 58(10):5714-8. PubMed ID: 25022586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
